Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI. The financing positions Pathos to execute its Foundry…
Pathos AI announced the acquisition of a majority stake in DeuterOncology, a Belgium-based company developing DO-2, a third-generation MET kinase inhibitor for…
DO-2 is a third-generation MET kinase inhibitor that demonstrated 100% tumor shrinkage in all evaluable MET exon 14 skipping NSCLC patients with only…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Pathos AI acquired a majority stake in Belgium-based DeuterOncology to advance DO-2, a deuterated third-generation MET kinase inhibitor identified through Pathos's Foundry AI platform. DO-2 targets MET-altered NSCLC and other solid tumors with a profile designed to reduce the peripheral edema seen in current MET inhibitors. Financial terms were not disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pathos AI, Inc. / DeuterOncology N.V. (this deal) | 2026 | — | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2026 deals · Oncology deals